{"filing":{"accession_number":"0001104659-26-118550","cik":"0001868279","ticker":"AVBP","company_name":"ArriVent BioPharma, Inc.","form":"8-K","filing_date":"2026-10-26","report_date":"2026-10-25","primary_document":"tm2628237d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926118550/tm2628237d1_8k.htm"},"events":[{"id":37730,"run_id":34772,"accession_number":"0001104659-26-118550","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"ArriVent disclosed initial Phase 1 clinical trial data for its lead ADC candidate ARR-217, presented at ESMO Congress 2026, showing a 44.8% objective response rate at the 6 mg/kg dose in colorectal cancer patients with a manageable safety profile. The company is advancing ARR-217 to Phase 1b dose optimization with data expected in 2027, representing a material clinical development milestone for the biopharmaceutical pipeline.","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-10-26","form":"8-K","submitted_at":null,"items":[{"id":42535,"accession_number":"0001104659-26-118550","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ArriVent disclosed initial Phase 1 clinical trial data for its lead ADC candidate ARR-217, presented at ESMO Congress 2026. The disclosure highlights encouraging efficacy results (44.8% ORR at 6 mg/kg in CRC patients) and a manageable safety profile, with advancement to Phase 1b dose optimization. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, as positive Phase 1 data directly impacts the development trajectory and investor assessment of the pipeline. While not a specific named event type, this is clearly an operational/strategic disclosure about a key development program milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:04:02.209828+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42536,"accession_number":"0001104659-26-118550","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ArriVent disclosed initial Phase 1 clinical trial data for its lead candidate ARR-217, showing a 44.8% objective response rate at the 6 mg/kg dose in colorectal cancer patients and a generally well-tolerated safety profile. This represents a material operational and clinical milestone for a clinical-stage biopharmaceutical company—the advancement of its lead ADC program into Phase 1b dose optimization with data expected in 2027. While not fitting a specific named event type, this clinical development milestone is clearly material to investors' assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:04:02.209828+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42535,"accession_number":"0001104659-26-118550","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ArriVent disclosed initial Phase 1 clinical trial data for its lead ADC candidate ARR-217, presented at ESMO Congress 2026. The disclosure highlights encouraging efficacy results (44.8% ORR at 6 mg/kg in CRC patients) and a manageable safety profile, with advancement to Phase 1b dose optimization. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, as positive Phase 1 data directly impacts the development trajectory and investor assessment of the pipeline. While not a specific named event type, this is clearly an operational/strategic disclosure about a key development program milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:04:02.209828+00:00","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-10-26"},{"id":42536,"accession_number":"0001104659-26-118550","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ArriVent disclosed initial Phase 1 clinical trial data for its lead candidate ARR-217, showing a 44.8% objective response rate at the 6 mg/kg dose in colorectal cancer patients and a generally well-tolerated safety profile. This represents a material operational and clinical milestone for a clinical-stage biopharmaceutical company—the advancement of its lead ADC program into Phase 1b dose optimization with data expected in 2027. While not fitting a specific named event type, this clinical development milestone is clearly material to investors' assessment of the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:04:02.209828+00:00","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-10-26"}]}
